• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆 IP-10 和 IL-6 与丙型肝炎相关肝硬化患者的 Child-Pugh B 级肝硬化相关:一项横断面研究。

Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study.

机构信息

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

Unidad de Análisis Clínicos, Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain.

出版信息

Sci Rep. 2020 Jun 25;10(1):10384. doi: 10.1038/s41598-020-67159-3.

DOI:10.1038/s41598-020-67159-3
PMID:32587340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7316790/
Abstract

We aimed to evaluate the association of plasma biomarkers linked to inflammation (bacterial translocation, inflammatory response, and endothelial dysfunction), coagulopathy, and angiogenesis with the severity of liver cirrhosis (assessed by the Child-Pugh-Turcotte score, CTP) and Child-Pugh B cirrhosis (CTP 7-9) in patients with advanced hepatitis C virus (HCV)-related cirrhosis. We carried out a cross-sectional study in 97 patients with advanced HCV-related cirrhosis (32 HCV-monoinfected and 65 HIV/HCV-coinfected). Plasma biomarkers were measured by ProcartaPlex multiplex immunoassays. The outcome variable was the CTP score and the Child-Pugh B cirrhosis (CTP 7-9). HIV/HCV-coinfected patients and HCV-monoinfected patients with advanced HCV-related cirrhosis had near-equivalent values of plasma biomarkers. Higher values of plasma biomarkers linked to an inflammatory response (IP-10, IL-8, IL-6, and OPG), endothelial dysfunction (sVCAM-1 and sICAM-1), and coagulopathy (D-dimer) were related to higher CTP values. The most significant biomarkers to detect the presence of Child-Pugh B cirrhosis (CTP 7-9) were IP-10 (p-value= 0.008) and IL-6 (p-value=0.002). The AUC-ROC values of IP-10, IL-6, and both biomarkers combined (IP-10+IL-6) were 0.78, 0.88, and 0.96, respectively. In conclusion, HIV infection does not appear to have a significant impact on the analyzed plasma biomarkers in patients with advanced HCV-related cirrhosis. However, plasma biomarkers linked to inflammation (inflammatory response and endothelial dysfunction) were related to the severity of liver cirrhosis (CTP score), mainly IP-10 and IL-6, which discriminated patients with Child-Pugh B concerning Child-Pugh A.

摘要

我们旨在评估与炎症(细菌易位、炎症反应和内皮功能障碍)、凝血异常和血管生成相关的血浆生物标志物与晚期丙型肝炎病毒(HCV)相关肝硬化患者的肝硬化严重程度(通过 Child-Pugh-Turcotte 评分,CTP)和 Child-Pugh B 肝硬化(CTP 7-9)的相关性。我们对 97 例晚期 HCV 相关肝硬化患者(32 例 HCV 单感染和 65 例 HIV/HCV 合并感染)进行了横断面研究。通过 ProcartaPlex 多重免疫分析测量血浆生物标志物。结局变量为 CTP 评分和 Child-Pugh B 肝硬化(CTP 7-9)。HIV/HCV 合并感染患者和 HCV 单感染患者的晚期 HCV 相关肝硬化患者的血浆生物标志物值相近。与炎症反应(IP-10、IL-8、IL-6 和 OPG)、内皮功能障碍(sVCAM-1 和 sICAM-1)和凝血异常(D-二聚体)相关的血浆生物标志物水平较高与较高的 CTP 值相关。检测 Child-Pugh B 肝硬化(CTP 7-9)存在的最显著的生物标志物是 IP-10(p 值=0.008)和 IL-6(p 值=0.002)。IP-10、IL-6 和两者联合生物标志物(IP-10+IL-6)的 AUC-ROC 值分别为 0.78、0.88 和 0.96。总之,HIV 感染似乎不会对晚期 HCV 相关肝硬化患者的分析血浆生物标志物产生重大影响。然而,与炎症(炎症反应和内皮功能障碍)相关的血浆生物标志物与肝硬化的严重程度(CTP 评分)相关,主要是 IP-10 和 IL-6,它们可以区分 Child-Pugh B 与 Child-Pugh A 患者。

相似文献

1
Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study.血浆 IP-10 和 IL-6 与丙型肝炎相关肝硬化患者的 Child-Pugh B 级肝硬化相关:一项横断面研究。
Sci Rep. 2020 Jun 25;10(1):10384. doi: 10.1038/s41598-020-67159-3.
2
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.成功的丙型肝炎病毒治疗可降低晚期肝硬化的HIV/丙型肝炎病毒合并感染患者的肝病严重程度和炎症生物标志物:一项队列研究。
Front Med (Lausanne). 2021 Feb 1;8:615342. doi: 10.3389/fmed.2021.615342. eCollection 2021.
3
Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients.HIV/HCV合并感染和HCV单一感染患者晚期肝硬化阶段的血浆代谢组学指纹图谱。
Liver Int. 2020 Sep;40(9):2215-2227. doi: 10.1111/liv.14580. Epub 2020 Jul 7.
4
Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.无论有无肝纤维化及是否合并HIV感染,活跃的丙型肝炎病毒(HCV)感染均与循环中干扰素-γ(IFN-γ)诱导蛋白10(IP-10)、可溶性CD163及炎性单核细胞水平升高有关。
Clin Res Hepatol Gastroenterol. 2017 Dec;41(6):644-655. doi: 10.1016/j.clinre.2017.04.007. Epub 2017 May 31.
5
Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.肝硬度升高与 HIV/丙型肝炎病毒合并感染患者的炎症和免疫激活生物标志物升高有关。
AIDS. 2018 Jun 1;32(9):1095-1105. doi: 10.1097/QAD.0000000000001787.
6
HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.直接作用抗病毒药物治愈 HCV 可改善 HIV/HCV 合并感染患者的肝脏和免疫标志物。
Front Immunol. 2021 Aug 23;12:723196. doi: 10.3389/fimmu.2021.723196. eCollection 2021.
7
Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.DAA 治疗后代谢组学的变化与 HIV/HCV 合并感染患者肝硬化和炎症的改善有关。
Biomed Pharmacother. 2022 Mar;147:112623. doi: 10.1016/j.biopha.2022.112623. Epub 2022 Jan 12.
8
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.直接作用抗病毒药物清除丙型肝炎病毒后肝硬化患者的肝功能:来自 PITER 队列的数据。
BMC Infect Dis. 2021 May 4;21(1):413. doi: 10.1186/s12879-021-06053-3.
9
Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCV-Coinfected Individuals.血浆炎症生物标志物与 HIV/HCV 共感染个体的晚期肝纤维化相关。
Int J Environ Res Public Health. 2020 Dec 17;17(24):9474. doi: 10.3390/ijerph17249474.
10
Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.肝硬度值可预测代偿期肝硬化的人类免疫缺陷病毒/丙型肝炎病毒合并感染患者的临床结局。
Hepatology. 2012 Jul;56(1):228-38. doi: 10.1002/hep.25616. Epub 2012 Jun 6.

引用本文的文献

1
The Causal Relationship between Inflammatory Cytokines and Liver Cirrhosis in European Descent: A Bidirectional Two-Sample Mendelian Randomization Study and the First Conclusions.欧洲血统人群中炎症细胞因子与肝硬化之间的因果关系:一项双向两样本孟德尔随机化研究及初步结论
Biomedicines. 2024 Oct 4;12(10):2264. doi: 10.3390/biomedicines12102264.
2
Artificial intelligence-based evaluation of prognosis in cirrhosis.基于人工智能的肝硬化预后评估。
J Transl Med. 2024 Oct 14;22(1):933. doi: 10.1186/s12967-024-05726-2.
3
Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis-Pathogenesis, Implications and Therapeutic Opportunities.

本文引用的文献

1
Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?丙型肝炎病毒对 CXCL10 分泌的免疫调节作用:CXCL10 能否成为慢性丙型肝炎的预后标志物?
J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
2
Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.肝静脉压力梯度变化可预测获得无干扰素治疗持续病毒学应答患者的肝失代偿。
Hepatology. 2020 Mar;71(3):1023-1036. doi: 10.1002/hep.30885. Epub 2019 Oct 14.
3
Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.
失代偿期肝硬化的营养不良和肌肉减少症相关门静脉高压症的发病机制、影响及治疗机会
Nutrients. 2023 Dec 21;16(1):35. doi: 10.3390/nu16010035.
4
Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis.血清白介素 6、10、12 和 23 水平与肝硬化严重程度的关系。
Med Arch. 2021 Jun;75(3):199-203. doi: 10.5455/medarh.2021.75.199-203.
5
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.成功的丙型肝炎病毒治疗可降低晚期肝硬化的HIV/丙型肝炎病毒合并感染患者的肝病严重程度和炎症生物标志物:一项队列研究。
Front Med (Lausanne). 2021 Feb 1;8:615342. doi: 10.3389/fmed.2021.615342. eCollection 2021.
肝硬化中固有免疫功能障碍的原因和后果。
Front Immunol. 2019 Feb 25;10:293. doi: 10.3389/fimmu.2019.00293. eCollection 2019.
4
Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy.免疫激活的可溶性标志物在无干扰素丙肝治疗期间差异正常化,并与AST、ALT、白蛋白及瞬时弹性成像的改善有选择性关联。
Pathog Immun. 2018 Sep 7;3(1):149-163. doi: 10.20411/pai.v3i1.242.
5
A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.一个变化的范例:丙型肝炎病毒/艾滋病病毒合并感染患者的管理和治疗。
Hepatol Int. 2018 Nov;12(6):500-509. doi: 10.1007/s12072-018-9896-4. Epub 2018 Sep 20.
6
Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.在伴有和不伴有 HIV 合并感染的肝硬化患者中,对所有口服 HCV 治疗有反应后肝功能的恢复相似。
J Viral Hepat. 2019 Jan;26(1):16-24. doi: 10.1111/jvh.12990. Epub 2018 Sep 27.
7
Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.抗 HCV 治疗可降低 HIV/HCV 共感染患者的免疫激活、微生物易位和 HIV DNA 水平。
J Infect Dis. 2018 Jul 13;218(4):624-632. doi: 10.1093/infdis/jiy136.
8
Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.肝硬度升高与 HIV/丙型肝炎病毒合并感染患者的炎症和免疫激活生物标志物升高有关。
AIDS. 2018 Jun 1;32(9):1095-1105. doi: 10.1097/QAD.0000000000001787.
9
Role of inflammatory response in liver diseases: Therapeutic strategies.炎症反应在肝脏疾病中的作用:治疗策略。
World J Hepatol. 2018 Jan 27;10(1):1-7. doi: 10.4254/wjh.v10.i1.1.
10
Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers.HIV感染导致衰老的基础科学与发病机制:潜在机制与生物标志物
AIDS. 2017 Jun 1;31 Suppl 2:S105-S119. doi: 10.1097/QAD.0000000000001441.